VivoSeq
Immunology

Autoimmune Diabetes

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Autoimmune Diabetes is an early-stage landscape with 0 programs across 1 company. The most active players are Diamyd Therapeutics AB.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Diamyd Therapeutics AB

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed6 · 60%
Unknown status3 · 30%
Withdrawn1 · 10%

Clinical Trials

Trial Activity

10 trials

Treatment of Latent Autoimmune Diabetes of the Adult
Completed·NNorwegian University of Science and Technology·N/A·NCT01140438·64 enrolled
GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial)
Completed·TTechnical University of Munich·Phase 2·NCT03364868·1,050 enrolled
Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune Diabetes
Completed·SSecond Xiangya Hospital of Central South University·Phase 4·NCT02407899·300 enrolled
Early Insulin Treatment in Patients With Latent Autoimmune Diabetes
Completed·LLund University Hospital·Phase 4·NCT01109927·42 enrolled
Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)
Completed·DDiamyd Therapeutics AB·Phase 2·NCT00456027·160 enrolled
Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)
Completed·EEuropean Foundation for the Study of Diabetes·Phase 1/2·NCT01159847·30 enrolled
Autoimmune Diabetes Accelerator Prevention Trial
Withdrawn·—·Phase 4·NCT02881528
Metformin Plus Insulin on Non-obese Autoimmune Diabetes
Unknown status·SSecond Xiangya Hospital of Central South University·Phase 4·NCT03513874·15 enrolled
Safety Study and Therapeutic Effects of Umbilical Cord Blood Treg on Autoimmune Diabetes
Unknown status·SSecond Xiangya Hospital of Central South University·Phase 1/2·NCT02932826·40 enrolled
Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes
Unknown status·SSecond Xiangya Hospital of Central South University·Phase 1/2·NCT03011021·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)